APA (7th ed.) Citation

JH, K., L, Q., LS, S., BK, A., E, R., Y, L., . . . HF, T. (2026). Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis. Open forum infectious diseases, 13(5), ofag279. https://doi.org/10.1093/ofid/ofag279

Chicago Style (17th ed.) Citation

JH, Ku, et al. "Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis." Open Forum Infectious Diseases 13, no. 5 (2026): ofag279. https://doi.org/10.1093/ofid/ofag279.

MLA (9th ed.) Citation

JH, Ku, et al. "Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis." Open Forum Infectious Diseases, vol. 13, no. 5, 2026, p. ofag279, https://doi.org/10.1093/ofid/ofag279.